CTLA4 and neoplasm: In terms of CAR-T cell function optimization, CRISPR technology significantly enhances anti-tumor activity and reduces the risk of allogeneic rejection by targeting and knocking down immune checkpoint genes (e.g., PD-1, CTLA-4) and endogenous T cell receptors (TRAC/TRBC) (Figure 3).